After yesterday's market close, the Goleta, CA-based medical technology company posted earnings of 19 cents per share, topping analysts' estimates of 7 cents per share.
Revenue rose 38.9% to $40.5 million year-over-year and surpassed Wall Street's projections of $34.7 million.
"2015 was marked by strong growth and operational execution across all areas of our business, with better than anticipated sales in a seasonally slower fourth quarter," CEO Raymond Huggenberger said in a statement.
Additionally, Inogen raised its guidance for 2016. The company now expects revenue between $187 million and $191 million compared to its previous forecast of $177 million to $183 million.
Inogen develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
About 1.17 million of the company's shares were traded by this afternoon, well above its average volume of 153,883 shares per day.
Separately, TheStreet Ratings Team has a "Hold" rating with a score of C- on the stock.
The primary factors that have impacted the rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks.
The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and increase in net income.
As a counter to these strengths, the team also finds weaknesses including disappointing return on equity, premium valuation and a decline in the stock price during the past year.
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
You can view the full analysis from the report here: INGN